Advantages of immune cell modulation in the treatment of autoimmune and inflammatory diseases

Immune cell modulators are a novel therapeutic class with the potential to deliver differentiated outcomes in autoimmune and inflammatory diseases including dermatology, gastroenterology, and rheumatology

  • Checkpoint agonists “hit the brakes” to restore immune balance​ and deliver differentiated outcomes

  • ANB032 (BTLA agonist) modulates activated immune cells:​

    • Agonize T cells (Th1, Th2, Th17, Th22)
    • Modulate dendritic cells
    • Agonize B cells

    Rosnilimab (PD-1 agonist) targets PD-1+ T cells through 3 MOAs:

    • Deplete PD-1high Teff cells​
    • Deplete PD-1high Tfh/Tph cells
    • Agonize PD-1int Teff cells
  • Membrane-proximal binding epitope and optimized Fc receptor binding affinity enables tight immune synapse and best-in-class potency

Teff=T effector cells; Tph cells=Peripheral helper cells; Tfh cells=Follicular helper cells.

Anaptys Publications and Relevant Literature

ANB032

  • Poster Presentation
February, 2024 - American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells

Luu et al., 2024

  • Poster Presentation
December, 2021 — Antibody Engineering & Therapeutics Conference

ANB032, a Novel BTLA/HVEM Therapeutic Antibody, Inhibited T cells Derived from Atopic Dermatitis Patients In-vitro

Hsu et al., 2021

  • Poster Presentation
November, 2021 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Soluble BTLA (sBTLA) is Induced Following Targeting of BTLA In-vivo by ANB032, a Novel BTLA/HVEM Modulator Therapeutic Antibody for the Treatment of Autoimmune Disease

Dahl et al., 2021

  • Poster Presentation
November, 2020 — Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

Discovery and Characterization of ANB032, a Novel BTLA/HVEM Checkpoint Modulator for Autoimmune/Inflammatory Disease

Dahl et al., 2020

Rosnilimab

  • Oral Presentation
May, 2024 — Digestive Disease Week (DDW) Annual Meeting

Optimizing PD-1 Agonist Signaling With Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2024

  • Poster Presentation
February, 2024 — European Crohn’s and Colitis Organisation (ECCO) Congress

Optimizing PD-1 Agonist Signaling with Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2024

  • Poster Presentation
November, 2023 — American College of Rheumatology (ACR) Convergence

Optimizing PD-1 Agonist Signaling with Membrane-Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2023

  • Journal Publication
June, 2020 — International Immunology

PD-1 and PD-1 Ligands: From Discovery to Clinical Application

Okazaki et al., 2020

  • Journal Publication
June, 2017 — Molecular Medicine Reports

Elevated Expression of PD‑1 on T Cells Correlates with Disease Activity in Rheumatoid Arthritis

Luu et al., 2018

  • Journal Publication
February, 2017 — Nature

Pathologically Expanded Peripheral T Helper Cell Subset Drives B Cells in Rheumatoid Arthritis

Rao et al., 2017

Imsidolimab

  • Oral Presentation
October, 2021 — European Academy of Dermatology and Venereology (EADV) Annual Congress

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial

Gudjonsson et al., 2021

  • Poster Presentation
May, 2018 — European Academy of Allergy and Clinical Immunology (EAACI) Congress

A Phase 1 Study of ANB019, an Anti-Interleukin-36-Receptor (IL-36R) Monoclonal Antibody, in Healthy Volunteers

Khanskaya et al., 2018

  • Journal Publication
November, 2013 — Journal of Investigative Dermatology

The Majority of Generalized Pustular Psoriasis Without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist

Sugiura et al., 2013

  • Journal Publication
August, 2012 — Current Opinion in Pharmacology

IL-36 in Psoriasis

Towne et al., 2012

  • Journal Publication
2012 — Expert Review of Dermatology

IL-36: a Potential Psoriasis Target?

Raison et al., 2012

  • Journal Publication
September, 2011 — The American Journal of Human Genetics

Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis

Onoufriadis et al., 2011

  • Journal Publication
August, 2011 — The New England Journal of Medicine

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

Marrakchi et al., 2011

  • Journal Publication
October, 2007 — Journal of Experimental Medicine

Opposing Activities of Two Novel Members of the IL-1 Ligand Family Regulate Skin Inflammation

Blumberg et al., 2007

Immuno-Oncology

  • Poster Presentation
2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics

Identification and Characterization of TSR-042, a Novel Anti-PD-1 Therapeutic Antibody

Laken et al., 2016

  • Poster Presentation
2016 — EORTC-NCI-American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics

Discovery of TSR-022, a Novel, Potent Anti-TIM-3 Therapeutic Antibody

Laken et al., 2016

  • Poster Presentation
2015 — American Association for Cancer Research Annual Meeting

Targeting PD-1, TIM-3 and LAG-3 in Combination for Improved Immunotherapy Combinations

Kehry et al., 2015

  • Poster Presentation
2015 — Keystone Symposium on Antibodies as Drugs

Generation of Anti-LAG-3 Monoclonal Antibodies for use in Immunotherapy Combinations

Jun et al., 2015

  • Poster Presentation
2014 — American Association for Cancer Research Special Conference on Tumor Immunology and Immunotherapy

Identification and Characterization of a Potent Anti-Human Tim-3 Antagonist

Correia et al., 2014

  • Poster Presentation
2014 — American Association for Cancer Research Annual Meeting

Generation of Antagonistic Anti-TIM-3 and LAG-3 Monoclonal Antibodies for Potential Novel Immunotherapy Combinations

Jun et al., 2014